drugset / Trial / NCT00185172

Olmesartan in Essential Hypertension

NCT00185172

Phase 3 Completed 2333 enrolled Sankyo Pharma Gmbh
RandomizedParallel-groupDouble-blindTreatment

Summary

To test the efficacy and safety of olmesartan in patients with essential hypertension.

Timeline

Start
2002-01
Primary completion
2005-06
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrochlorothiazide Unknown Oral
Subject Olmesartan medoxomil Unknown Oral